Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Monday, November 9, 2020. San Francisco, California (October 28, 2020) — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its third quarter 2020 financial results on November 9, […]
San Francisco, California (October 7, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics, today announced it has expanded an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine for COVID-19 and other vaccine candidates. The manufacturing services will be performed via Centaur Biopharmaceutical Services (Centaur), a […]
/wp-content/uploads/2017/09/KindredBioHeader2017.png00Katja Buhrer/wp-content/uploads/2017/09/KindredBioHeader2017.pngKatja Buhrer2020-10-07 08:08:022020-10-07 08:08:03Kindred Biosciences Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates
Study demonstrated 100% efficacy in prevention of parvovirus infection in prophylactic pivotal study of KIND-030 San Francisco, California (September 16, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030, a monoclonal antibody targeting canine […]
SAN FRANCISCO, September 9, 2020 — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will participate in the H.C. Wainwright Global Investment Conference on September 14-15, the Cantor Global Healthcare Conference on September 16, and the Lake Street Best Ideas Growth Conference on September 17. Dr. Richard Chin, […]
/wp-content/uploads/2017/09/KindredBioHeader2017.png00Katja Buhrer/wp-content/uploads/2017/09/KindredBioHeader2017.pngKatja Buhrer2020-09-09 08:06:482020-09-09 08:06:49Kindred Biosciences to Participate in H.C. Wainwright Global Investment Conference, Cantor Global Healthcare Conference and Lake Street Best Ideas Growth Conference
San Francisco, California (August 5, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2020 and provided updates on its programs. For the second quarter of 2020, KindredBio reported net revenues of $39.6 million […]
-0.02 (-0.45%)
Kindred Biosciences to Announce Third Quarter 2020 Financial Results
/in Frontpage, Investor, News /by Katja BuhrerCompany to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Monday, November 9, 2020. San Francisco, California (October 28, 2020) — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its third quarter 2020 financial results on November 9, […]
Kindred Biosciences Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (October 7, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics, today announced it has expanded an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine for COVID-19 and other vaccine candidates. The manufacturing services will be performed via Centaur Biopharmaceutical Services (Centaur), a […]
Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody
/in Frontpage, Investor, News /by Katja BuhrerStudy demonstrated 100% efficacy in prevention of parvovirus infection in prophylactic pivotal study of KIND-030 San Francisco, California (September 16, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030, a monoclonal antibody targeting canine […]
Kindred Biosciences to Participate in H.C. Wainwright Global Investment Conference, Cantor Global Healthcare Conference and Lake Street Best Ideas Growth Conference
/in Frontpage, Investor, News /by Katja BuhrerSAN FRANCISCO, September 9, 2020 — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will participate in the H.C. Wainwright Global Investment Conference on September 14-15, the Cantor Global Healthcare Conference on September 16, and the Lake Street Best Ideas Growth Conference on September 17. Dr. Richard Chin, […]
Kindred Biosciences Announces Second Quarter 2020 Financial Results
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (August 5, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2020 and provided updates on its programs. For the second quarter of 2020, KindredBio reported net revenues of $39.6 million […]